Markets India

Emcure Pharma shares jumped 10% to a 52-week high of Rs 2,180.80 on the BSE after strong Q2 FY27 results and a revised full-year growth guidance, with Jefferies raising its target price by 8%.

Emcure Pharma Shares Surge 10% on FY27 Guidance Hike, Jefferies Raises Target Price

Emcure Pharma's shares surged 10% to a 52-week high of Rs 2,180.80 on the BSE following Q2 FY27 results showing a 29.3% YoY rise in adjusted PAT to Rs 325.1 crore and 24.3% YoY revenue growth to Rs 2,820.5 crore. Jefferies raised its target price to Rs 2,500 from Rs 2,320, citing stronger-than-expected performance and improved EBITDA margins. The company also raised FY27 revenue growth guidance to over 20% from a mid-teens forecast. EBITDA margins improved by 103 basis points to 20.4%, driven by operational efficiency gains. Emcure’s India growth rose 12% YoY, with Zuventus contributing significantly to the expansion. The revised guidance and robust financials signal enhanced market penetration and competitive positioning, supported by regulatory approvals for products like Lenacapavir and Liposomal Amphotericin B. Stakeholders, including brokerages like Jefferies and HDFC Securities, benefit from the positive outlook and updated target prices. The company’s focus on international markets and product launches, such as Amphotericin B in 20 European countries, underscores its growth strategy. Pending regulatory approvals for Lenacapavir in India and Liposomal Amphotericin B in Brazil/Mexico remain critical to long-term success.

Emcure plans product launches in 20 European countries for Amphotericin B and has filed the Lenacapavir injection dossier with WHO and US FDA. Regulatory approvals for Lenacapavir in India and Liposomal Amphotericin B in Brazil/Mexico are pending.

Emcure Pharma’s revised guidance and strong results boost investor confidence, but success hinges on new product launches and regulatory approvals, with international expansion and domestic performance as key uncertainties.

Topics: Pharmaceuticals, Financial Results, Stock Performance, EBITDA, Regulatory Approvals, India Markets, Healthcare Innovation

#EmcurePharma #FY27Guidance #JefferiesTargetPrice #Pharmaceuticals #RegulatoryApprovals #IndiaMarkets #HealthcareInnovation

Source: ET Markets